Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2′-deoxycytidine

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1193-1199

  Dubovsky, Jason A ^a   Powers, John J ^a   Gao, Yang ^a   Mariusso, Luis F ^a   Sotomayor, Eduardo M ^a   Pinilla Ibarz, Javier A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

5 Aza 2 deoxycytidine; Epigenetic; Interferon gamma; T helper cell; T bet

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; TRANSCRIPTION FACTOR T BET;

ARTICLE; CELL POLARITY; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DEMETHYLATION; DONOR; EPIGENETICS; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MOLECULAR GENETICS; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE REPOLARIZATION; TH1 CELL; TH2 CELL;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL POLARITY; CELL PROLIFERATION; CELLS, CULTURED; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERFERON-GAMMA; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TH2 CELLS;

EID: 80051472069     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.02.007     Document Type: Article

References (27)

1. Ramsay A.G., Johnson A.J., Lee A.M., Gorgun G., Le Dieu R., Blum W. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008.
2. Krackhardt A.M., Witzens M., Harig S., Hodi F.S., Zauls A.J., Chessia M. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 2002, 100(6):2123-2131.
3. Ouillette P., Erba H., Kujawski L., Kaminski M., Shedden K., Malek S.N. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008, 68(4):1012-1021.
4. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer Statistics. CA Cancer J Clin 2008.
5. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties [Review]. Annu Rev Immunol 1989, 7:145-173.
6. Horna P., Sotomayor E.M. Cellular and molecular mechanisms of tumor-induced T-cell tolerance. Curr Cancer Drug Targets 2007, 7(1):41-53.
7. Mellstedt H., Choudhury A. T and B cells in B-chronic lymphocytic leukaemia: faust mephistopheles and the pact with the devil. Cancer Immunol Immunother 2006, 55(2):210-220.
8. Scrivener S., Goddard R.V., Kaminski E.R., Prentice A.G. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma 2003, 44(3):383-389.
9. Kay N.E., Rai K.R., O'Brien S. Chronic lymphocytic leukemia: current and emerging treatment approaches. Clin Adv Hematol Oncol 2006, 4(11 Suppl. 22). pp. 1-10; quiz 11-12.
10. Rassenti L.Z., Jain S., Keating M.J., Wierda W.G., Grever M.R., Byrd J.C., et al. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 2008, 112(5):1923-1930.
11. Fulci V., Chiaretti S., Goldoni M., Azzalin G., Carucci N., Tavolaro S., et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007, 109(11):4944-4951.
12. Wilson C.B., Rowell E., Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009, 9(2):91-105.
13. Araki Y., Wang Z., Zang C., Wood W.H., Schones D., Cui K., et al. Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells. Immunity 2009, 30(6):912-925.
14. Lee Y.K., Turner H., Maynard C.L., Oliver J.R., Chen D., Elson C.O., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009, 30(1):92-107.
15. Wei G., Wei L., Zhu J., Zang C., Hu-Li J., Yao Z., et al. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 2009, 30(1):155-167.
16. Quintas-Cardama A., Santos F.P., Garcia-Manero G. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010, 7(8):433-444.
17. Dubovsky J.A., Villagra A., Powers J.J., Wang H.W., Pinilla-Ibarz J., Sotomayor E.M. Circumventing immune tolerance through epigenetic modification. Curr Pharm Des 2010, 16(3):268-276.
18. Dubovsky J.A., McNeel D.G., Powers J.J., Gordon J., Sotomayor E.M., Pinilla-Ibarz J.A. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res 2009, 15(10):3406-3415.
19. Chapoval S., Dasgupta P., Dorsey N.J., Keegan A.D. Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL-4 and STAT6. J Leukoc Biol 2010, 87(6):1011-1018.
20. Frydecka I., Kosmaczewska A., Bocko D., Ciszak L., Wolowiec D., Kuliczkowski K., et al. Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia. Br J Cancer 2004, 90(10):2042-2048.
21. Scrivener S., Kaminski E.R., Demaine A., Prentice A.G. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Haematol 2001, 112(4):959-964.
22. Schoenborn J.R., Dorschner M.O., Sekimata M., Santer D.M., Shnyreva M., Fitzpatrick D.R., et al. Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-gamma. Nat Immunol 2007, 8(7):732-742.
23. Janson P.C., Marits P., Thorn M., Ohlsson R., Winqvist O. CpG methylation of the IFNG gene as a mechanism to induce immunosuppression [correction of immunosupression] in tumor-infiltrating lymphocytes. J Immunol 2008, 181(4):2878-2886.
24. Yano S., Ghosh P., Kusaba H., Buchholz M., Longo D.L. Effect of promoter methylation on the regulation of IFN-gamma gene during in vitro differentiation of human peripheral blood T cells into a Th2 population. J Immunol 2003, 171(5):2510-2516.
25. Blum K.A., Liu Z., Lucas D.M., Chen P., Xie Z., Baiocchi R., Benson D.M. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol 2010, 150(2):189-195.
26. Stewart D.J., Issa J.P., Kurzrock R., Nunez M.I., Jelinek J., Hong D. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009, 15(11):3881-3888.
27. Dubovsky J.A., Wang D., Powers J.J., Berchmans E., Smith M.A., Wright K.L. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res 2010.